23616-33-3

Basic information

• Product Name: 2-CHLORO-1,6-NAPHTHYRIDINE
• Synonyms: 2-CHLORO-1,6-NAPHTHYRIDINE
• CAS NO: 23616-33-3
• Molecular Formula: C8H5ClN2
• Molecular Weight: 164.5917
• Product Categories: CHIRAL CHEMICALS
• Mol File: 23616-33-3.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 298.922 °C at 760 mmHg
• Flash Point: 162.817 °C
• Appearance: /
• Density: 1.35 g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.663
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 2.89±0.30(Predicted)
• CAS DataBase Reference: 2-CHLORO-1,6-NAPHTHYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-1,6-NAPHTHYRIDINE(23616-33-3)
• EPA Substance Registry System: 2-CHLORO-1,6-NAPHTHYRIDINE(23616-33-3)

Safety Data

• Hazardous Substances Data: 23616-33-3(Hazardous Substances Data)

Usage

General Description

2-Chloro-1,6-naphthyridine is a chemical compound with the molecular formula C10H6ClN. It is a halogenated naphthyridine derivative and belongs to the class of heterocyclic compounds. This chemical is commonly used in the pharmaceutical industry as a building block for the synthesis of various pharmaceutical products. It possesses potential therapeutic properties and has been studied for its antimicrobial, antioxidant, and antitumor activities. Additionally, 2-Chloro-1,6-naphthyridine has also been investigated for its use as a pesticide. It is important to handle this compound with care due to its potential health hazards and environmental impact.

InChI:InChI=1/C8H5ClN2/c9-8-2-1-6-5-10-4-3-7(6)11-8/h1-5H

Upstream product

• 13534-98-0 3-bromopyridin-4-amine 
• 23616-29-7 1,6-naphthyridin-2(1H)-one 

Downstream Products

• 17965-81-0 2-amino-1,6-naphthyridine 

Relevant articles and documents

PYRROLO[2,3-C]PYRIDINES AS IMAGING AGENTS FOR NEUROFIBRILARY TANGLES

Pyrrolopyridine compounds of formula (I) or their pharmaceutically acceptable salts are disclosed, which may be suitable for imaging tau aggregates, b-sheet aggregates, beta-amyloid aggregates or alpha- synuclein aggregates, and hence are useful in binding and imaging tau aggregates in Alzheimer's patients. More specifically, the compounds are used as tracers in positron emission tomography (PET) imaging to study tau deposits in brain in vivo to allow diagnosis of Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology. Futher, the compounds are useful for measuring clinical efficacy of therapeutic agents for Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology.

Integrin expression inhibitors

The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. In the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, —CH═CH— or —(CR4bR5b)mb— (wherein R4b and R5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and mb means an integer of 1 or 2); R1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or —CO—NH—; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.